Treatment of herpes

Details Treatment of herpes Treatment of herpes

2005-10-07

2008-12-09

Salimi, Ali R. (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S007100

Reexamination Certificate

active

07462454

ABSTRACT:
The present invention includes methods for the treatment of a herpes simplex virus infection comprising the administration of inhibitors of gamma interferon, tumor necrosis alpha and interleukin-1.

REFERENCES:
patent: 4704362 (1987-11-01), Itakura et al.
patent: 4897264 (1990-01-01), Novick et al.
patent: 4968607 (1990-11-01), Dower
patent: 5126262 (1992-06-01), Matsui et al.
patent: 5221789 (1993-06-01), Novick et al.
patent: 5578707 (1996-11-01), Novick
patent: 5626843 (1997-05-01), Skurkovich et al.
patent: 5759808 (1998-06-01), Casterman et al.
patent: 5800988 (1998-09-01), Casterman et al.
patent: 5840526 (1998-11-01), Casterman et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 6015695 (2000-01-01), Casterman et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 87/02671 (1987-05-01), None
Bird et al., “Single-Chain Antigen-Binding Proteins,”Science, vol. 242, pp. 423-426, 1988.
Engleman et al., “Antibodies to a Soluble Form of a Tumor Necrosis Factor (TNF) Receptors Have TNF-Like Activity,”The Journal of Biological Chemistry, vol. 265, No. 24, pp. 14497-14504, 1990.
Feldmann et al., “Interferons and Autoimmunity,”Interferon 9, Academic Press, pp. 75-89, 1987.
Fountoulakis et al., “Purification and Biochemical Characterization of a Soluble Human Interferon γ Receptor Expressed inEscherichia coli,” J. Biol. Chem., vol. 265, pp. 13268-13275, 1990.
Fountoulakis et al., “Interferon γ Receptor Extracellular domain Expressed as IgG Fusion Protein in Chinese Hamster Ovary Cells,”The Journal of Biological Chemistry, vol. 270, pp. 3958-3964, 1995.
Gillam et al., “Site-Specific Mutagenesis Using Synthetic Oligodeoxyribonucleotide Primers: I. Optimum Conditions and Minimum Oligodeoxyribonucleotide Length,”Gene, vol. 8, pp. 81-97, 1979.
Gray et al., “Cloning of Human Tumor Necrosis Factor (TNF) Receptor cDNA and Expression of Recombinant Soluble TNF-binding Protein,”Proc. Natl. Acad. Sci. USA, vol. 87, pp. 7380-7384, 1990.
Gringeri et al., “Anti-Alpha Interferon Immunization: Safety and Immunogenicity in Asymptomatic HIV Positive Patients at High Risk of Disease Progression,”Cellular and Molecular Biology, vol. 41, pp. 381-387, 1995.
Gringeri et al., “Absence of Clinical, Virological, and Immunological Signs of Progression in HIV-1 Infected Patients Receiving Active Anti-Interferon-α Immunization: A 30-month Follow-up Report,”Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 13, pp. 55-67, 1996.
Gu et al., “Construction and Expression of Mouse-Human Chimeric Antibody SZ-51 Specific for Activated Platelet P-Selectin,”Thrombosis and Hematocyst; vol. 77, pp. 755-759, 1997.
Hamers-Casterman et al., “Naturally Occurring Antibodies Devoid of Light Chains,”Letters to Nature, vol. 363, pp. 446-448, 1993.
Huston, et al., “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced inEscherichia coli,” Proc. Natl. Acad. Sci., USA, vol. 85, pp. 5879-5883, 1988.
Matsuda et al., “Establishment of an Interleukin 6 (IL 6) Cell Stimulatory Factor 2-Dependent Cell Line and Preparation of Anti-IL 6 Monoclonal Antibodies,”Eur. J. Immunol., vol. 18, pp. 951-956, 1988.
Mesa et al., “Interferon-γ Receptor Extracellular Domain-IgG Fusion Protein Produced in Chinese Hamster Ovary Cells as Mixture of Glycoforms,”Journal Of Interferon and Cytokine Research, vol. 15, pp. 309-315, 1995.
Ohshima et al., “Polyclonal Antibody Against an Inducible Form of Nitric Oxide Synthase Purified from the Liver of Rats Treated with Propionibacterium Acnes and Lipopolysaccharide,” vol. 187, pp. 1291-1297, 1992.
Peppel et al., “A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity,”J. Exp. Med. vol. 174, pp. 1483-1489, 1991.
Queen et al., “Cell-Type Specific Regulation of a κ Immunoglobulin Gene by Promoter and Enhancer Elements.”Immunol. Rev., vol. 89, pp. 49-68, 1986.
Roberts et al., “Generation of an Antibody With Enhanced Affinity and Specificity for its Antigen by Protein Engineering,” Nature, vol. 328, pp. 731-734, 1987.
Sastry et al., “Cloning of the Immunological Repertoire inEscherichia colifor Generation of Monoclonal Catalytic Antibodies: Construction of a Heavy Chain Variable Region-Specific cDNA Library,”Proc. Nat'l. Acad. Sci. USA, vol. 86, pp. 5728-5732, 1989.
Schall et al., “Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor,”Cell, vol. 61, pp. 361-370, 1990.
Seligmann et al., “Heavy Chain Diseases: Current findings and Concepts,”Immunological Rev. vol. 48, pp. 145-167, 1979.
Singh et al., Dysregulated Expression of IFN-γ and IL-10 and impaired IFN-γ Mediated Responses at Different Disease Stages in Patients with Genital Herpes Simplex Virus-2 Infection,Clin. Exp. Immunol., vol. 133, pp. 97-107, 2003.
Skurkovich et al., “Immunosuppressive Effect of an Anti-interferon Serum,”Nature, vol. 247, pp. 551-552, Feb. 22, 1974.
Skurkovich et al., “The Probable Role of Interferon in Allergy,”Annals of Allergy, vol. 35, pp. 356-360, Dec. 1975.
Skurkovich et al., “Aberrant IFN May Help HIV Survive and Replicate; Its Removal in AIDS Patients May Halt This Process and Help Restore the Immune System,”Journal of IFN Research, vol. 12, Suppl. 1, p. S110, 1992.
Skurkovich et al., “A Disturbance of Interferon Synthesis With the Hyperproduction of Unusual Kinds of Interferon can Trigger Autoimmune Disease and Play a Pathogenetic Role in AIDS: The Removal of These Interferons can be Therapeutic,”Medical Hypotheses, vol. 41, pp. 177-185, 1993.
Skurkovich et al., “A Disturbance of Interferon Synthesis With the Hyperproduction of Unusual Kinds of Interferon can Trigger Autoimmune Disease and Play a Pathogenetic Role in AIDS: The Removal of These Interferons can be Therapeutic,”Medical Hypotheses, vol. 42, pp. 27-35, 1994.
Tuszynski et al., “Thrombospondin Promotes Platelet Aggregation,”Blood, vol. 72, pp. 109-115, 1988.
Ward et al. “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted FromEscherichia coli,” Nature, vol. 341, pp. 544-546, 1989.
Wright et al., “Genetically Engineered Antibodies: Progress and Prospects,”Critical Rev. in Immunol. vol. 12, pp. 125-168, 1992.
Zagury et al., Toward a New Generation of Vaccines: The Anti-Cytokine Therapeutic Vaccines,Proc. Nat'l. Acad. Sci., USA, vol. 98(14), pp. 8024-8029, 2001.

Affiliated with

Also associated with

Rating

Treatment of herpes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of herpes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of herpes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4032908